A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/Keynote-775 Meeting Abstract
| Authors: | Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A.; Colomba, E.; Miller, D.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I.; Shapira, R.; Ushijima, K.; Sakata, J.; Yonemori, K.; Kim, Y. M.; Guerra, E. M.; Sanli, U. A.; McCormack, M.; Huang, J.; Smith, A. D. |
| Abstract Title: | A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/Keynote-775 |
| Meeting Title: | IGCS 2021 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2021 Aug 30-Sep 2 |
| Meeting Location: | Virtual |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2021-11-01 |
| Start Page: | A4 |
| End Page: | A5 |
| Language: | English |
| ACCESSION: | WOS:000773625600009 |
| DOI: | 10.1136/ijgc-2021-IGCS.8 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O008/#785 -- Source: Wos |
